

1 **Genetically downregulated interleukin-6 signaling is associated with a**
2 **favorable cardiometabolic profile: a phenome-wide association study**

3
4 Marios K. Georgakis, MD, PhD¹, Rainer Malik, PhD¹, Xue Li, PhD^{2,3}, Dipender Gill, BMBCh,
5 PhD⁴, Michael G. Levin, MD⁵, Ha My T. Vy, PhD⁶, Renae Judy, MS⁷, Marylyn Ritchie, PhD⁸,
6 Shefali S. Verma, PhD⁸, Regeneron Genetics Center⁹, Girish N. Nadkarni, MD^{6,10,11}, Scott
7 M. Damrauer, MD^{7,12}, Evropi Theodoratou, PhD^{2,13}, Martin Dichgans, MD^{1,14,15}

8 ¹Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-
9 University LMU, Munich, Germany; ²Centre of Global Health, Usher Institute, University of
10 Edinburgh, Edinburgh, UK; ³School of Public Health and the Second Affiliated Hospital, Zhejiang
11 University, Hangzhou, China; ⁴Department of Epidemiology and Biostatistics, School of Public
12 Health, Imperial College London, London, United Kingdom; ⁵Division of Cardiovascular Medicine,
13 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
14 USA; ⁶The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount
15 Sinai, New York, USA; ⁷Department of Surgery, Perelman School of Medicine, University of
16 Pennsylvania, Philadelphia, USA; ⁸Department of Genetics, Perelman School of Medicine, University
17 of Pennsylvania, Philadelphia, USA; ⁹Regeneron Genetics Center, Tarrytown, New York, USA;
18 ¹⁰Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai,
19 New York, USA; ¹¹Department of Medicine, Icahn School of Medicine at Mount Sinai, New York,
20 USA; ¹²Department of Surgery, Corporal Michael Crescenz VA Medical Center, Philadelphia,
21 Pennsylvania, USA; ¹³Edinburgh Cancer Research Centre, Institute of Genetics and Molecular
22 Medicine, University of Edinburgh, Edinburgh, UK; ¹⁴Munich Cluster for Systems Neurology
23 (SyNergy), Munich, Germany; ¹⁵German Centre for Neurodegenerative Diseases (DZNE), Munich,
24 Germany

25 **Corresponding author:** Martin Dichgans, MD

26 Institute for Stroke and Dementia Research,

27 Ludwig-Maximilians-University, Munich, Germany

28 Feodor-Lynen-Str. 17, 81377 Munich, Germany,

29 T: +49-89-4400-46018, E: martin.dichgans@med.uni-muenchen.de

1 **Abstract**

2 **Background:** Interleukin-6 (IL6) signaling is a key inflammatory pathway widely implicated
3 in the pathogenesis of multiple diseases including autoimmune, vascular, and metabolic
4 disorders. While IL6-receptor (IL6R) inhibitors are already in use for the treatment of
5 autoimmune diseases, their repurposing potential and safety profile is still debated.

6 **Methods:** We used 7 genetic variants at the *IL6R* locus as proxies for IL6 signaling
7 downregulation and explored their effects on 1,428 clinical outcomes in a phenome-wide
8 association study (PheWAS) using data from the UK Biobank (339,256 unrelated
9 individuals). Significant associations were meta-analyzed with data from the Penn Medicine
10 (10,244 individuals) and BioMe (9,054 individuals) Biobanks for validation. We further
11 investigated associations between genetically downregulated IL6 signaling and 366
12 biomarkers and endophenotypes of human disease in the UK Biobank and other
13 phenotype-specific consortia. All associations were examined by Mendelian randomization
14 (MR) analyses scaled to the effects of tocilizumab, a monoclonal antibody targeting IL6R.

15 **Results:** The PheWAS-MR analyses showed significant associations with 16 clinical
16 outcomes and 17 biomarkers following correction for multiple comparisons. Genetically
17 downregulated IL6 signaling was associated with a lower risk of several atherosclerotic
18 phenotypes including ischemic heart disease (OR: 0.84, 95%CI: 0.77-0.90) and abdominal
19 aortic aneurysm (OR: 0.44, 95%CI: 0.29-0.67). We further found significant associations
20 with lower risk of type 2 diabetes (OR: 0.80, 95%CI: 0.73-0.88), lower glycated hemoglobin
21 A1c (HbA1c) levels (beta: -0.07, 95%CI: -0.08 to -0.05), and higher HDL-cholesterol levels
22 (beta: 0.04, 95%CI: 0.02-0.06). In accord with clinical trials examining pharmacological IL6
23 blockade, genetically downregulated IL6 signaling was associated with higher risk of
24 neutropenia and bacterial infections (cellulitis and urinary tract infections) and with higher
25 hemoglobin concentrations. We further found significant associations with higher risk of
26 atopic dermatitis and higher levels of the pro-allergic cytokine interleukin-4.

1 **Conclusions:** Genetic IL6 signaling downregulation associates with a lower risk of vascular
2 outcomes and a more favorable cardiometabolic profile. These findings further support a
3 repurposing of IL6R blockade for lowering cardiovascular risk while also informing on
4 potential side effects.

5 **Keywords:** interleukin-6; inflammation; atherosclerosis; diabetes; cardiovascular disease;
6 high-density lipoprotein cholesterol

7

1 Introduction

2 Interleukin-6 (IL6) is a key cytokine that is involved in the activation and regulation of
3 immune responses, tissue regeneration, and metabolism.¹ IL6 plays a critical role in the
4 pathogenesis of multiple inflammatory disorders^{2, 3} and anti-inflammatory approaches
5 targeting the IL6 signaling cascade have gained great attention. Antibodies against the IL6
6 receptor (IL6R) are used for the treatment of rheumatoid arthritis⁴ and other autoimmune
7 disorders.^{5, 6} Accumulating experimental, epidemiological, and clinical evidence further
8 supports a broader role of IL6 signaling in human disease, as has specifically been
9 demonstrated for cardiovascular, metabolic, and psychiatric disorders.^{3, 7, 8}

10 Still, it remains unknown whether pharmacological IL6R blockade could be effectively
11 repurposed for the treatment or prevention of diseases beyond current indications. Also,
12 any potential benefits would need to be balanced against the side-effects of such
13 approaches. Both tocilizumab and sarilumab, the IL6R inhibitors currently in use, have been
14 found to be associated with an increased rate of infections,⁹ hyperlipidemia^{4, 10} and
15 hepatotoxicity.^{4, 9} Yet, it remains unknown whether these adverse effects are inherently
16 linked to the downregulation of IL6 signaling or represent compound-specific properties.
17 Furthermore, less common side-effects could have remained undetected in previous clinical
18 trials.

19 A comprehensive understanding of the repurposing opportunities and unknown side-effects
20 of downregulation of IL6 signaling would help prioritizing indications that should be moved
21 forward to clinical trials. While observational studies could provide such information, the risk
22 of bias due to confounding by indication remains high in observational settings.¹¹ The
23 growing availability of genome-wide association studies (GWAS) and the development of
24 large-scale biobanks linked to health records offer the possibility to study drug effects by
25 use of genetic data.¹²⁻¹⁴ Specifically, Mendelian randomization (MR) allows the use of
26 genetic variants to proxy traits of interest and explore widespread associations with
27 outcomes in phenome-wide association studies (PheWAS).¹⁵ MR overcomes key limitations

1 of observational studies, such as confounding and reverse causation, and allows for
2 investigation of causal effects on outcomes.^{16, 17}

3 We recently identified a set of 7 genetic variants in the locus of the *IL6R* gene that showed
4 remarkably similar effects on upstream (soluble IL6R and IL6) and downstream (C-reactive
5 protein [CRP] and fibrinogen) molecules in the IL6 signaling cascade compared to those
6 derived from clinical trials for tocilizumab.¹⁸ Here, we used these variants as a proxy of IL6
7 signaling downregulation and performed an MR-PheWAS study to explore potential
8 repurposing opportunities and unknown side-effects associated with IL6R blockade. We
9 first examined effects on clinical outcomes in a sample of 339,256 White British individuals
10 from the population-based UK Biobank study. We subsequently examined the identified
11 signals in two independent samples of 10,244 and 9,054 European American individuals
12 from the Penn Medicine Biobank (PMBB) and the BioMe Biobank in the US, respectively.
13 Finally, we explored the effects of genetically downregulated IL6 signaling on multiple
14 disease-related biomarkers including hematological, biochemical, metabolomic,
15 inflammatory, immunological, hemodynamic, and anthropometric traits in data from
16 phenotype-specific genetic consortia.

17

18 **Methods**

19 ***Data sources and Ethics statement***

20 This study follows the MR-STROBE guidelines.¹⁹ Data for clinical outcomes are from UK
21 Biobank. Data from Penn Medicine and BioMe Biobanks were used for validation. Data for
22 biomarkers were obtained from the UK Biobank or publicly available summary statistics.
23 Supporting data for the UK Biobank analyses are available in the online-only Data
24 Supplement. Supporting data from Penn Medicine and BioMe Biobanks are available upon
25 request. Analyses were performed in R (v3.5.0; The R Foundation for Statistical
26 Computing).

1 Participants in all studies provided informed consent and all studies obtained ethical
2 approval from institutional review boards. We accessed individual-level data from the UK
3 Biobank data following approval of an application by the UK Biobank Ethics and
4 Governance Council (application #2532). For the Penn Medicine and BioMe Biobanks,
5 individual-level data were analyzed from investigators of the studies (ML, RJ, MR, SV, SD
6 for Penn Medicine and HNV, GN for BioMe) after receiving approval for the current study
7 from the University of Pennsylvania Institutional Review Board and the Institutional Review
8 Board of the Icahn School of Medicine, respectively. We then accessed the derived
9 summary statistics to meta-analyze them with the UK Biobank data.

10

11 ***Selection of genetic instruments***

12 The exposure trait in this study was IL6R-mediated downregulation of the IL6 signaling
13 cascade. We used as genetic instruments 7 single nucleotide polymorphisms (SNPs) within
14 or close to the *IL6R* gene, which have previously been validated to proxy the biochemical
15 effects of pharmacological IL6R inhibition.¹⁸ Instrument selection is detailed elsewhere.¹⁸
16 Briefly, variants were located within the *IL6R* gene or a region 300 kB upstream or
17 downstream of it (**Supplementary Figure 1**) and were selected on the basis of their
18 associations with lower levels of CRP that is downstream to IL6R-mediated signaling and
19 reflects the activity of the IL6 signaling pathway.^{3, 20} The variants were derived from a
20 GWAS of 204,402 individuals of European ancestry,²¹ associated with circulating CRP
21 levels at genome-wide significance ($p < 5 \times 10^{-8}$) and were clumped for linkage disequilibrium
22 at $r^2 < 0.1$ according to the 1000G European reference panel. Aside from their effects on
23 CRP levels the 7 genetic variants were also associated with higher levels of soluble IL6
24 receptor (sIL6R) and IL6, which are upstream molecules in the pathway, as well as with
25 lower levels of fibrinogen, another downstream molecule in the IL6 signaling cascade.¹⁸ The
26 effects of all 7 genetic variants on circulating sIL6R, IL6, CRP, and fibrinogen levels were
27 directionally consistent with downregulation of the IL6 signaling pathway, as depicted in

1 **Supplementary Figure 2.** Three of the selected variants were within the *IL6R* gene; to
2 minimize emergence of potential pleiotropic effects through neighboring genes we
3 performed sensitivity analyses restricted to these variants. All SNPs have been shown to be
4 of sufficient strength ($F > 10$) for use in MR analyses, thus minimizing risk of weak
5 instrument bias.¹⁸ The genetic instruments are provided in **Supplementary Table 1** along
6 with their effects on circulating CRP, fibrinogen, sIL6R, and IL6 levels. The proportion of
7 variance of the circulating biomarker levels explained by each of the SNPs was estimated
8 according to a previously described formula.²² The 7 SNPs explained 0.55% and 0.24% of
9 the variance of CRP and fibrinogen levels, respectively, and 71.5% and 0.51% of the
10 variance of sIL6R and IL6, respectively.

11

12 ***Phenome-wide association study in the UK Biobank***

13 The UK Biobank is a population-based prospective cohort study that recruited 503,317
14 individuals aged 40-69 years in 2006-2010. Extensive baseline measurements including
15 biochemical and genotype data were linked with national medical records (inpatient hospital
16 episode records, primary general practitioner data, cancer registry, death registry) for
17 longitudinal follow-up. The current analysis was constrained to a subset of unrelated White
18 British individuals with high-quality genotype data in order to minimize the influence of
19 diverse population structure within UK Biobank. The largest possible subset of individuals
20 without relatedness was identified using an algorithm implemented in the R package "*i-*
21 *graph (v1.0.1)*" developed by Bycroft and colleagues.²³ UK Biobank genotype imputation
22 was conducted based on a merged reference panel of the Haplotype Reference
23 Consortium (HRC) panel, the UK10K panel and the 1000 Genome Phase 3 panel.²³ All 7
24 SNPs used in current study were on the HRC panel. A total of 339,256 individuals were
25 included in the PheWAS analyses.

26 Outcomes to be explored were defined by the PheCODE scheme.²⁴ This scheme
27 automatically excludes patients that have similar or potentially overlapping disease states

1 from the corresponding control group. We used the International Classification of Diseases
2 (ICD) versions 9 and 10 to identify cases in the medical records, with both incident and
3 prevalent cases included. A map matching ICD-9 and -10 codes to phecodes was used, as
4 previously described (https://phewascatalog.org/phecodes_icd10).²⁵

5 We applied logistic regression to explore the effects of each SNP on each outcome
6 adjusting for age, sex, the UK Biobank assessment center attended, east and north
7 coordinates of home address, and the first five ancestral principal components. Based on
8 power calculations, ≥ 120 cases would be required to detect odds ratios (OR) ≥ 2 or ≤ 0.5 at
9 $p < 0.05$ scaled to the CRP-decreasing effects of tocilizumab in the subsequent MR analyses
10 (**Supplementary Figure 3**). Hence, all outcomes with < 120 cases were excluded from
11 analyses resulting in a total of 1,032 outcomes that were eventually included in the
12 PheWAS analyses.

13

14 ***Associations with biomarkers***

15 We further derived association estimates of each SNP with the following biomarkers: (i) 25
16 serum and urine biomarkers available in the biochemistry panel of the UK Biobank (353,579
17 individuals); (ii) 36 hematological traits, as derived from the summary statistics of the study
18 by Astle *et al.*²⁶ based on the UK Biobank and the INTERVAL population (173,480
19 European individuals); (iii) 124 nuclear magnetic resonance (NMR)-measured serum lipids
20 and metabolites, as derived from the publicly available summary statistics provided by
21 Kettunen *et al.*²⁷ (24,925 individuals of European ancestry); (iv) circulating levels of 41
22 cytokines and growth factors, derived from the publicly available summary statistics by
23 Ahola-Olli *et al.*²⁸ (8,293 individuals of Finnish ancestry); (v) 25 infectious disease antigens
24 available in a sub-sample of 9,431 individuals from the UK Biobank; (vi) 6 hemodynamic
25 traits that were available in the UK Biobank (408,228 individuals); (vii) 18 glycemic traits
26 made publicly available from a series of analyses from the MAGIC Consortium (up to
27 133,010 individuals)²⁹; and (viii) 91 anthropometric traits derived from the summary

1 statistics made publicly available by the GIANT Consortium (different sample sizes, up to
2 322,154 individuals).³⁰ The data sources for these studies are described in **Supplementary**
3 **Table 2**.

4 For the genetic analyses of serum and urine biomarkers in the UK Biobank we performed
5 linear regression, adjusting for age, sex, genotyping chip, assessment center and the first
6 20 ancestral principal components. Continuous traits were quantile-normalized, forcing
7 phenotypes to a $N(0, 1)$ distribution. For the infectious disease antigens, we performed
8 logistic regression analyses specifying as cases all those individuals surpassing pre-
9 specified cutoffs for seropositivity for single or multiple antigens as suggested by UK
10 Biobank (available at <https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/infdisese.pdf>) using
11 the same covariates as for the linear regression analysis. To ensure numerical stability, we
12 performed linear transformation of covariates to a distribution of mean=0 and variance=1.
13 The details of the GWAS analyses for the remaining traits that were derived from publicly
14 available summary statistics are provided in the original publications (**Supplementary**
15 **Table 2**).

16

17 ***Statistical analyses – Mendelian randomization***

18 We used the SNP-specific association estimates for the clinical outcomes and the
19 biomarkers that we derived from the abovementioned analyses or that we extracted from
20 the respective summary statistics and ran inverse-variance weighted (IVW) MR analyses to
21 obtain a composite effect of IL6 signaling downregulation on the outcomes of interest.³¹ To
22 provide clinically relevant results, the composite effect estimates were scaled to the CRP-
23 decreasing effect of tocilizumab (a decrease of CRP levels by 67% on a dose of 8 mg/kg, 4
24 to 24 weeks post-administration).²⁰ We corrected for multiple comparisons with the false
25 discovery rate (FDR) method. We considered as statistically significant all those outcomes
26 for which q-values were <0.05 .

1 IVW MR was our primary approach. While the selection of instruments on a specific gene
2 reduces the possibility of invalid variants,³² the derived estimates might still be biased in
3 case of directional pleiotropy. Hence, for outcomes reaching statistical significance in the
4 main analyses, we assessed heterogeneity across the SNP-specific MR estimates in the
5 IVW MR analyses with the Cochran's Q statistic as a measure of overall pleiotropy.³³ For
6 significant outcomes, we further applied sensitivity MR analyses that are more robust to the
7 inclusion of pleiotropic variants. First, we used the weighted median estimator, which
8 provides consistent estimates as long as at least half of the variants used in the MR
9 analysis are valid.³⁴ Second, we restricted our selection of instruments to SNPs within the
10 *IL6R* gene, to avoid potential pleiotropic effects through genes neighboring *IL6R* and
11 increase confidence in the effects of the instruments through IL6 signaling. As finally
12 significant results, we considered all those that (i) showed an FDR-derived $q < 0.05$ in the
13 main IVW analyses, (ii) showed no heterogeneity (Cochran Q-derived $p > 0.10$), and (iii)
14 showed directionally consistent associations of $p < 0.05$ in both sensitivity analyses.

15

16 ***Validation in the Penn Medicine and BioMe Biobanks***

17 For phenotypes reaching statistical significance after FDR control in original analyses, we
18 further examined their associations with genetically downregulated IL6 signaling in the
19 PMBB (University of Pennsylvania) and the BioMe Biobank (Icahn School of Medicine,
20 Mount Sinai). PMBB is a longitudinal genomics and precision medicine study in which
21 participants consent to linkage of genomic information and biospecimens to electronic
22 health records; more than 60,000 individuals are currently enrolled. The BioMe Biobank is
23 an electronic health record-linked clinical care biobank cohort that enrolls participants non-
24 selectively from across the Mount Sinai Health System; the data set comprises over 45,000
25 participants from diverse ancestries (African, Hispanic/Latino, European and Other
26 ancestries), with accompanying genome-wide genotyping data and a wide array of
27 phenotypes derived from interview-based questionnaire, electronic health records and ICD-

1 codes. For the current analyses, we considered only individuals of European ancestry, who
2 underwent genome-wide genotyping and had available electronic health record data
3 (PMBB: 10,244 and BioMe: 9,054). Clinical diagnoses in both biobanks were also coded
4 according to the PheCODE schema. The MR analyses were repeated in these cohorts and
5 the effect estimates from the IVW analyses were then meta-analyzed with those derived
6 from the UK Biobank using random-effects models. Outcomes that reached the original
7 FDR-corrected threshold in the meta-analysis of UKB, PMBB and BioMe were considered
8 statistically significant.

9

10 **Results**

11 ***PheWAS: associations of IL6 signaling downregulation with clinical outcomes***

12 The baseline descriptive characteristics of the UK Biobank participants that were included
13 in the PheWAS analyses are presented in **Supplementary Table 3**. Baseline
14 characteristics of individuals included in the validation cohorts (PMBB and BioMe biobanks)
15 are presented in **Supplementary Table 4**. The number of outcomes examined per
16 diagnostic category are presented in **Supplementary Table 5**, whereas the results of the
17 MR analyses along with the number of cases and controls considered per outcome are
18 provided in **Supplementary Table 6**. There were 35 outcomes reaching the statistical
19 significance threshold of $FDR < 0.05$ in the primary IVW MR analyses ($p < 1.7 \times 10^{-3}$) that
20 pooled the effect estimates across the effects of the 7 SNPs used as instruments (**Figure**
21 **1**). Out of those, 33 (94%) showed no evidence of heterogeneity ($p > 0.10$) while exhibiting
22 consistent associations (same direction and $p < 0.05$) in the sensitivity MR analyses
23 (weighted median, gene-restricted IVW), thus showing low probability of pleiotropy
24 (**Supplementary Table 7** and **Figure 1**).

25 The detailed results from the inverse-variance weighted analyses for these outcomes are
26 presented in **Table 1**. In the meta-analysis of the effect estimates derived from the UK

1 Biobank with those from the PMBB and BioMe Biobanks, 16 of the 24 outcomes with
2 sufficient statistical power for validation remained statistically significant ($p < 1.7 \times 10^{-3}$; **Figure**
3 **2** and detailed results in **Supplementary Table 8**). Most of the significant results (7/16,
4 44%) referred to outcomes related to cardiovascular disease. Among them, there were
5 associations of genetically downregulated IL6 signaling with lower risk of angina pectoris,
6 ischemic heart disease, coronary atherosclerosis, abdominal aortic aneurysm, abnormal
7 heart sounds, and varicose veins of the lower extremities. Furthermore, we found
8 associations with lower risk of diabetes mellitus, and particularly type 2 diabetes mellitus, as
9 well as with lower risk of decubitus ulcer. On the opposite direction, we found associations
10 of genetically downregulated IL6 signaling with higher risk of cellulitis and abscess of
11 arm/hand, urinary tract infections, other disorders of urethra and urinary tract, female
12 infertility, unspecified erythematous conditions, atopic dermatitis, and hypotension.

13 For nine additional outcomes that reached statistical significance in the primary UK Biobank
14 analysis (benign neoplasm of kidney and other urinary organs, anterior horn cell disease,
15 acute pericarditis, respiratory complications, cholelithiasis with acute cholecystitis or other
16 cholecystitis, cyst of bone, loose body in joint), there were no sufficient number of cases in
17 the PMBB and BioMe biobanks to allow for validation (**Table 1** and **Supplementary Table**
18 **8**).

19

20 ***Associations with biomarkers***

21 To gain additional insights into the relationship between IL6 signaling and subclinical
22 endophenotypes relevant to human disease, we explored associations between genetically
23 downregulated IL6 signaling and eight categories of 366 biomarkers. The results, along with
24 the number of individuals examined in each analysis are presented in **Supplementary**
25 **Table 9**. In the main IVW analysis, a total of 25 outcomes reached the threshold of
26 statistical significance of $FDR < 0.05$ ($p < 1.8 \times 10^{-4}$). Of them, 17 associations remained

1 consistent (same direction and $p < 0.05$) in sensitivity analyses and did not show any
2 heterogeneity ($p > 0.10$) (**Supplementary Table 10** and **Supplementary Figure 4**).

3 **Table 2** displays the results of the IVW MR analyses for these biomarkers, which are also
4 graphically presented in **Figure 3**. Aside from the expected associations with higher CRP
5 and lower IL6 levels that we have previously reported,¹⁸ we found associations with a
6 number of hematological traits. Specifically, genetically downregulated IL6 signaling was
7 associated with higher mean corpuscular hemoglobin and volume, higher hemoglobin
8 concentration, higher hematocrit, and lower red cell distribution width, as well as with higher
9 monocyte count and percentage, and lower granulocyte percentage. Furthermore, we found
10 genetically downregulated IL6 signaling to be associated with a lower glycated hemoglobin
11 (HbA1c). Among serum lipids and metabolites, we found genetically downregulated IL6
12 signaling to be associated with a higher total cholesterol concentration and higher HDL
13 cholesterol (**Supplementary Figure 5**). There were also significant associations with lower
14 cystatin C, and with higher levels of the cytokines IL4 (interleukin-4) and CTACK
15 (Cutaneous T-Cell Attracting Chemokine).

16

17 **Discussion**

18 This study used large-scale data from multiple sources to explore the phenotypic
19 consequences of genetic predisposition to IL6 signaling downregulation. Our findings can
20 be summarized as follows: genetic downregulation of IL6 signaling was associated with (i)
21 lower risk of atherosclerotic vascular phenotypes (coronary artery disease and abdominal
22 aortic aneurysm), (ii) lower HbA1c and lower risk of type 2 diabetes mellitus, (iii) increases
23 in cholesterol levels, mainly due to an effect on HDL cholesterol, (iv) higher risk of skin and
24 urinary tract infections and neutropenia, (v) higher risk of atopic phenotypes and higher
25 interleukin-4 levels, and (vi) increases in hemoglobin and related phenotypes, as well as
26 monocyte counts.

1 As an important novel finding, we provide evidence for a causal effect of IL6 signaling on
2 the risk of type 2 diabetes. Aside from effects on risk of type 2 diabetes in three
3 independent cohorts, we also found directionally consistent effects on HbA1c levels, thus
4 further validating our results. Our findings complement and expand existing data from other
5 sources supporting an involvement of IL6 signaling in the development of hyperglycemia
6 and diabetes. Analyses of case series of diabetic and non-diabetic patients with rheumatoid
7 arthritis have shown that pharmacological IL6R inhibition leads to reductions in HbA1c
8 levels.^{35, 36} Moreover, meta-analyses of cohort studies show significant associations
9 between elevated IL6 levels and incident type 2 diabetes.³⁷ Experimental studies in mice
10 further suggest an effect of IL6 on insulin resistance that can be reversed by IL6 signaling
11 blockade.³⁸ As such, there is triangulation of evidence to support IL6-centered approaches
12 as a strategy for lowering risk of hyperglycemia and type 2 diabetes. Future trials on IL6R
13 inhibition should add glycemic traits and incident type 2 diabetes to the outcomes under
14 study.

15 Clinical trials exploring pharmacological IL6R blockade have reported increases in total
16 cholesterol levels.^{4, 10} However, it remains unclear how IL6R blockade influences the
17 different lipid fractions, which have been shown to differentially influence vascular risk.³⁹⁻⁴¹
18 Here, we explored associations with a panel of >100 lipid fractions and metabolites.
19 Although we found genetic predisposition to downregulation of IL6 signaling to be indeed
20 associated with higher total cholesterol levels, this increase was largely restricted to HDL-
21 and not LDL-cholesterol. We further found a significant association with Apolipoprotein-A1,
22 the hallmark of HDL particles, but not Apolipoprotein-B that is contained in non-HDL
23 particles (**Supplementary Figure 5**). While clinical trials have shown no benefit of HDL-
24 raising approaches for large vessel disease,⁴² recent evidence suggests that genetic
25 elevation of HDL cholesterol levels is associated with lower risk of cerebral small vessel
26 disease⁴⁰ and chronic kidney disease.⁴³ Whether these associations could be clinically
27 meaningful remains to be tested in future clinical trials. Still, the association of IL6 signaling
28 downregulation with lower risk of type 2 diabetes and higher HDL levels, both key

1 components of the current definition of metabolic syndrome, suggest a beneficial effect of
2 IL6R blockade on the metabolic profile of individuals at risk for cardiovascular disease.

3 The associations between genetically downregulated IL6 signaling and lower risk of multiple
4 phenotypes related to coronary artery disease (coronary atherosclerosis, angina pectoris,
5 chronic ischemic heart disease) and aortic aneurysm agrees with previous clinical,⁴⁴
6 genetic,^{18, 20, 45} and experimental^{46, 47} data demonstrating a role of IL6 signaling in
7 atherosclerosis. Accumulating data from clinical trials also support the efficacy of targeting
8 specific inflammatory pathways for lowering vascular risk.^{48, 49} The CANTOS trial studied a
9 monoclonal antibody targeting IL1 β , a cytokine upstream to IL6, and demonstrated
10 reductions in the rates of vascular events among patients with a history of myocardial
11 infarction.⁴⁸ Secondary analyses from CANTOS showed that the residual vascular risk after
12 IL1 β inhibition could be explained by IL6 levels,⁴⁴ thus supporting direct IL6 signaling
13 inhibition as a potentially even more effective strategy.⁷ By showing that genetic IL6
14 signaling downregulation associates with both a more favorable cardiometabolic profile and
15 a decreased risk of vascular endpoints, our findings provide additional support towards
16 repurposing IL6R blockade approaches for lowering vascular risk.

17 Aside from demonstrating cardiometabolic effects of IL6 signaling, our MR approach
18 captured some of the known side-effects of IL6R blockade that have previously been
19 reported by clinical trials. Specifically, we found associations of genetic predisposition to IL6
20 signaling downregulation with higher risks of infections (cellulitis and urinary tract infections)
21 and atopic dermatitis.^{4, 9, 50} By analysing biomarker data, we identified associations with
22 specific endophenotypes that might mediate these findings. Specifically, genetically
23 downregulated IL6 signaling was associated with neutropenia that might explain its effects
24 on bacterial infections, but also with higher IL4 levels, a key cytokine in allergic reactions.
25 The higher risk associated with atopic reactions was further highlighted by a significant
26 association with asthma in the UK Biobank, which we could not validate in the independent
27 cohorts. Given the high prevalence of atopic dermatitis and asthma in the general
28 population,⁵¹ future research should explore in more detail the role of IL6 in atopic reactions

1 and whether IL6R blockade could lead to exacerbations in patients suffering from these
2 diseases. We further found genetically downregulated IL6 signaling to be associated with
3 higher hemoglobin concentrations and a number of other related biomarkers. Similar effects
4 have been previously reported for pharmacological IL6R blockade and have been attributed
5 to improvements in chronic disease anemia associated with inflammation and autoimmune
6 diseases.⁵² Additionally, genetic IL6 signaling downregulation was associated with
7 monocyte count and percentage. This is a finding not previously reported and the clinical
8 significance, as well as the underlying mechanisms need to be further evaluated.

9 An important methodological consideration of Mendelian randomization analyses includes
10 the potentially pleiotropic effects of the genetic variants used in the analyses on clinical
11 outcomes through pathways other than the IL6 signaling cascade. To address this, we
12 restricted our analyses to the *IL6R* locus, thus minimizing effects through other pathways.
13 Furthermore, we addressed this issue in sensitivity analyses by further restricting our
14 selection to SNPs *within* the *IL6R* gene. If the 7 SNPs had effects on clinical outcomes that
15 act through different pathways, it would be expected that these effects would not be similar
16 across the 7 SNPs, and there would be heterogeneity in the pooled effect sizes. Hence,
17 heterogeneity was a criterion for selecting “significant” outcomes. All outcomes showing
18 significant heterogeneity in the analyses ($p < 0.10$) were filtered out of significant results. We
19 believe that this set of sensitivity analyses minimized the possibility of unrecognized
20 pleiotropic effects.

21 Our study has several strengths. Utilizing the most recent genetic data and a recently
22 published and significantly expanded set of instruments¹⁸ we were sufficiently powered to
23 expand the results derived from previous efforts exploring the effects of genetically
24 downregulated IL6 signaling on clinical outcomes.^{20, 45} By applying a pre-specified approach
25 for filtering the significant outcomes in the current study including strict thresholds for
26 statistical significance, consistency across alternative statistical methods, lack of
27 heterogeneity between individual variants, and validation in independent cohorts, we
28 ensured robustness of our findings. Using CRP levels as a proxy for downstream IL6

1 signaling further enabled us to scale the derived association estimates to the reported
2 effects of tocilizumab, thus providing clinically meaningful estimates that might be
3 comparable to those obtained from future trials. Finally, we expanded our analyses to
4 biomarkers and endophenotypes, allowing cross-validation of the findings across multiple
5 levels of phenotypes.

6 Our study also has limitations. First, to proxy IL6 signaling we used CRP levels, which
7 increase in response to the activation of the IL6 cascade.⁵³ However, IL6 signaling is a
8 complex cascade with a (exerted through membrane-bound IL6R expressed in limited
9 tissues) and a trans-signaling component (exerted through the more widely expressed
10 soluble IL6R).⁵³ The two sub-pathways exert unique actions,⁵³ but disentangling them with
11 genetic instruments goes beyond the limits of MR. Second, by design, MR analyses assess
12 the effects of lifetime downregulated IL6 signaling, which might differ from a shorter
13 pharmacological inhibition with IL6R blockade. Third, there might be unknown pleiotropic
14 effects of the genetic proxies used as instruments in the current study that might bias the
15 reported associations. Of note, however, the results were remarkably consistent in
16 sensitivity MR analyses that are more robust to the inclusion of pleiotropic variants, as well
17 as in analyses restricted within the *IL6R* gene. Fourth, while the sample size of the
18 discovery UK Biobank cohort was very large (>300,000 individuals) and provided power to
19 explore associations with outcomes, the sample sizes of the validation cohorts were rather
20 small and did not offer sufficient power to explore the robustness of nine signals for
21 relatively rare outcomes that came up in the discovery cohort. Fifth, our results were solely
22 based on individuals of European origin, and might thus not apply to other ethnicities. Sixth,
23 while we used the largest available datasets to detect genetic variants that influence the IL6
24 signaling cascade, the proportion of the variance explained in biomarkers of the pathway
25 was relatively low. As such, we cannot rule out that additional variants might influence the
26 pathway and future analyses in larger datasets might provide additional insights towards
27 detecting more such variants. Noteworthy, as long as the results are robust and not
28 influenced by pleiotropy, we would not expect the number of genetic instruments used to

1 influence the validity of the derived effects estimates. Finally, while genetic variants used as
2 proxies for IL6 signaling influence CRP and other upstream and downstream molecules of
3 the IL6 signaling cascade, the exact cellular and molecular significance of each variant
4 remains unknown.

5 In conclusion, this study used large-scale data to systematically explore the phenotypic
6 consequences of genetically downregulated IL6 signaling. We highlight key associations
7 with a range of cardiometabolic traits including lower risks of type 2 diabetes and
8 hyperglycaemia, higher HDL cholesterol levels, and lower risk of atherosclerotic outcomes.
9 As such, our findings highlight the potential of repurposing IL6R blockade as a strategy for
10 improving cardiometabolic profile and lowering vascular risk. These effects should be
11 further explored in clinical trials and weighted against the side-effects of IL6-targeting
12 approaches.

13

14 **Acknowledgements:** This research has been conducted using the UK Biobank Resource
15 (UK Biobank application 2532, “UK Biobank stroke study: developing an in-depth
16 understanding of the determinants of stroke and its subtypes”). We thank the following
17 studies and consortia for making summary data from GWASs publicly available: the
18 INTERVAL study, the YFS and FINRISK studies, the MAGIC Consortium, the GWAS for
19 NMR-measured metabolites by Kettunen *et al.*, and the GIANT Consortium. We thank the
20 personnel and the participants of the Penn Medicine and BioMe biobanks.

21 **Data availability:** The genetic variants used as instruments in the current study, as well as
22 summary statistics derived for the examined outcomes are available as Supplementary
23 Material. Raw UK Biobank data may be derived through application. Data from the Penn
24 Medicine and BioMe Biobanks are also available upon application to principal investigators.

25 **Regeneron Genetics Center Banner Author List and Contribution Statements:** All
26 authors/contributors are listed in alphabetical order. RGC Management and Leadership

1 Team: Goncalo Abecasis, Ph.D., Aris Baras, M.D., Michael Cantor, M.D., Giovanni
2 Coppola, M.D., Aris Economides, Ph.D., John D. Overton, Ph.D., Jeffrey G. Reid, Ph.D.,
3 Alan R. Shuldiner, M.D. Sequencing and Lab Operations: Christina Beechert, Caitlin
4 Forsythe, M.S., Erin D. Fuller, Zhenhua Gu, M.S., Michael Lattari, Alexander Lopez, M.S.,
5 John D. Overton, Ph.D., Thomas D. Schleicher, M.S., Maria Sotiropoulos Padilla, M.S.,
6 Karina Toledo, Louis Widom, Sarah E. Wolf, M.S., Manasi Pradhan, M.S., Kia
7 Manoochehri, Ricardo H. Ulloa. Genome Informatics: Xiaodong Bai, Ph.D., Suganthi
8 Balasubramanian, Ph.D., Leland Barnard, Ph.D., Andrew Blumenfeld, Yating Chai, Ph.D.,
9 Gisu Eom, Lukas Habegger, Ph.D., Young Hahn, Alicia Hawes, B.S., Shareef Khalid,
10 Jeffrey G. Reid, Ph.D., Evan K. Maxwell, Ph.D., John Penn, M.S., Jeffrey C. Staples, Ph.D.,
11 Ashish Yadav, M.S. Planning, Strategy, and Operations: Paloma M. Guzzardo, Ph.D.,
12 Marcus B. Jones, Ph.D., Lyndon J. Mitnaul, Ph.D.

13 **Funding:** M. Georgakis has received funding from the Onassis Foundation. D. Gill was
14 supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart
15 Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. S.
16 Damrauer is supported by the US Department of Veterans Affairs (IK2-CX001780); this
17 work does not express the vies of the US Department of Veterans Affairs or the US
18 Government. E. Theodoratou is funded by CRUK (C31250/A22804). This project has
19 received funding from the European Union’s Horizon 2020 research and innovation
20 programme (666881), SVDs@target (to MD; 667375), CoSTREAM (to MD); the DFG as
21 part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198)
22 and the CRC 1123 (B3; to MD); the Corona Foundation (to MD); the Fondation Leducq
23 (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the
24 Brain; to MD); the e:Med program (e:AtheroSysMed; to MD) and the FP7/2007-2103
25 European Union project CVgenes@target (grant agreement number Health-F2-2013-
26 601456; to MD).

27 **Disclosures:** Dr Gill is employed part-time by Novo Nordisk. The other authors have no
28 conflicts of interest to disclose.

1

2 **References**

- 3 1. Schaper F and Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade.
4 *Cytokine Growth Factor Rev.* 2015;26:475-87.
- 5 2. Scheller J, Chalaris A, Schmidt-Arras D and Rose-John S. The pro- and anti-inflammatory
6 properties of the cytokine interleukin-6. *Biochim Biophys Acta.* 2011;1813:878-88.
- 7 3. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To
8 Identify Novel Targets for Atheroprotection. *Circ Res.* 2016;118:145-56.
- 9 4. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten
10 H, Bauer D, Ignacio Vargas J and Lee EB. Efficacy and safety of sarilumab monotherapy versus
11 adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH):
12 a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis.* 2017;76:840-847.
- 13 5. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A,
14 Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J
15 and Schreiber S. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in
16 Crohn's disease (ANDANTE I and II). *Gut.* 2019;68:40-48.
- 17 6. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid
18 MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH and
19 Collinson N. Trial of Tocilizumab in Giant-Cell Arteritis. *N Engl J Med.* 2017;377:317-328.
- 20 7. Ridker PM, MacFadyen JG, Thuren T and Libby P. Residual inflammatory risk associated
21 with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab:
22 further rationale for the development of targeted anti-cytokine therapies for the treatment of
23 atherothrombosis. *Eur Heart J.* 2019.
- 24 8. Borovcanin MM, Jovanovic I, Radosavljevic G, Pantic J, Minic Janicijevic S, Arsenijevic N
25 and Lukic ML. Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance? *Front Psychiatry.*
26 2017;8:221.
- 27 9. Nishimoto N, Ito K and Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in
28 Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term
29 extensions. *Mod Rheumatol.* 2010;20:222-32.
- 30 10. Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J and Sattar N.
31 Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with
32 tocilizumab or adalimumab in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2016;75:1806-12.
- 33 11. Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei
34 F and Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication
35 in observational studies. *J Clin Epidemiol.* 2010;63:64-74.
- 36 12. Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, Theodoratou E, Elliott P,
37 Denny JC, Malik R, Evangelou E, Dehghan A, Dichgans M and Tzoulaki I. Use of Genetic Variants
38 Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects. *Circulation.* 2019;140:270-
39 279.

- 1 13. Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, Vangjeli C,
2 Weale ME, Mattsson H, Kilpelainen E, Sleiman PMA, Reilly DF, McElwee J, Maranville JC,
3 Chatterjee AK, Bhandari A, Nguyen KH, Estrada K, Reeve MP, Hutz J, Bing N, John S, MacArthur
4 DG, Salomaa V, Ripatti S, Hakonarson H, Daly MJ, Palotie A, Hinds DA, Donnelly P, Fox CS, Day-
5 Williams AG, Plenge RM and Runz H. Phenome-wide association studies across large population
6 cohorts support drug target validation. *Nat Commun.* 2018;9:4285.
- 7 14. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R,
8 Karlsson A, Santos R, Overington JP, Hingorani AD and Casas JP. The druggable genome and
9 support for target identification and validation in drug development. *Sci Transl Med.* 2017;9.
- 10 15. Walker VM, Davey Smith G, Davies NM and Martin RM. Mendelian randomization: a novel
11 approach for the prediction of adverse drug events and drug repurposing opportunities. *Int J*
12 *Epidemiol.* 2017;46:2078-2089.
- 13 16. Holmes MV, Ala-Korpela M and Smith GD. Mendelian randomization in cardiometabolic
14 disease: challenges in evaluating causality. *Nat Rev Cardiol.* 2017;14:577-590.
- 15 17. Roberts R. Mendelian Randomization Studies Promise to Shorten the Journey to FDA
16 Approval. *JACC Basic Transl Sci.* 2018;3:690-703.
- 17 18. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM and Dichgans M. Interleukin-6
18 Signaling Effects on Ischemic Stroke and other Cardiovascular Outcomes: A Mendelian
19 Randomization Study. *Circ Genom Precis Med.* 2020.
- 20 19. Davey Smith G, Davies NM, Dimou N, Egger M, Gallo V, Golub R, Higgins JP, Langenberg
21 C, Loder EW, Richards JB, Richmond RC, Skrivankova VW, Swanson SA, Timpson NJ, Tybjaerg-
22 Hansen A, VanderWeele TJ, Woolf BA and Yarmolinsky J. STROBE-MR: Guidelines for
23 strengthening the reporting of Mendelian randomization studies. *PeerJ Preprints.* 2019;7:e27857v1.
- 24 20. Interleukin-6 Receptor Mendelian Randomisation Analysis C, Swerdlow DI, Holmes MV,
25 Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, Mooijaart
26 SP, Ireland HA, Leusink M, Langenberg C, Li KW, Palmén J, Howard P, Cooper JA, Drenos F,
27 Hardy J, Nalls MA, Li YR, Lowe G, Stewart M, Bielinski SJ, Peto J, Timpson NJ, Gallacher J, Dunlop
28 M, Houlston R, Tomlinson I, Tzoulaki I, Luan J, Boer JM, Forouhi NG, Onland-Moret NC, van der
29 Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A,
30 Topor-Madry R, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Ferrucci L,
31 Bandenelli S, Tanaka T, Meschia JF, Singleton A, Navis G, Mateo Leach I, Bakker SJ, Gansevoort
32 RT, Ford I, Epstein SE, Burnett MS, Devaney JM, Jukema JW, Westendorp RG, Jan de Borst G, van
33 der Graaf Y, de Jong PA, Mailand-van der Zee AH, Klungel OH, de Boer A, Doevendans PA,
34 Stephens JW, Eaton CB, Robinson JG, Manson JE, Fowkes FG, Frayling TM, Price JF, Whincup
35 PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Redline S, Lange LA, Kumari M, Wareham
36 NJ, Verschuren WM, Benjamin EJ, Whittaker JC, Hamsten A, Dudbridge F, Delaney JA, Wong A,
37 Kuh D, Hardy R, Castillo BA, Connolly JJ, van der Harst P, Brunner EJ, Marmot MG, Wassel CL,
38 Humphries SE, Talmud PJ, Kivimaki M, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson
39 JG, Hakonarson H, Reiner AP, Keating BJ, Sattar N, Hingorani AD and Casas JP. The interleukin-6
40 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
41 *Lancet.* 2012;379:1214-24.

- 1 21. Ligthart S, Vaez A, Vosa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ,
2 Tanaka T, Naderi E, Rose LM, Wu Y, Karlsson R, Barbalic M, Lin H, Pool R, Zhu G, Mace A, Sidore
3 C, Trompet S, Mangino M, Sabater-Lleal M, Kemp JP, Abbasi A, Kacprowski T, Verweij N, Smith AV,
4 Huang T, Marzi C, Feitosa MF, Lohman KK, Kleber ME, Milaneschi Y, Mueller C, Huq M,
5 Vlachopoulou E, Lytikainen LP, Oldmeadow C, Deelen J, Perola M, Zhao JH, Feenstra B, LifeLines
6 Cohort S, Amini M, Group CIW, Lahti J, Schraut KE, Fornage M, Suktitipat B, Chen WM, Li X, Nutile
7 T, Malerba G, Luan J, Bak T, Schork N, Del Greco MF, Thiering E, Mahajan A, Marioni RE, Mihailov
8 E, Eriksson J, Ozel AB, Zhang W, Nethander M, Cheng YC, Aslibekyan S, Ang W, Gandin I, Yengo
9 L, Portas L, Kooperberg C, Hofer E, Rajan KB, Schurmann C, den Hollander W, Ahluwalia TS, Zhao
10 J, Draisma HHM, Ford I, Timpson N, Teumer A, Huang H, Wahl S, Liu Y, Huang J, Uh HW, Geller F,
11 Joshi PK, Yanek LR, Trabetti E, Lehne B, Vozzi D, Verbanck M, Biino G, Saba Y, Meulenbelt I,
12 O'Connell JR, Laakso M, Giulianini F, Magnusson PKE, Ballantyne CM, Hottenga JJ, Montgomery
13 GW, Rivadineira F, Rueedi R, Steri M, Herzig KH, Stott DJ, Menni C, Franberg M, St Pourcain B,
14 Felix SB, Pers TH, Bakker SJL, Kraft P, Peters A, Vaidya D, Delgado G, Smit JH, Grossmann V,
15 Sinisalo J, Seppala I, Williams SR, Holliday EG, Moed M, Langenberg C, Raikonen K, Ding J,
16 Campbell H, Sale MM, Chen YI, James AL, Ruggiero D, Soranzo N, Hartman CA, Smith EN,
17 Berenson GS, Fuchsberger C, Hernandez D, Tiesler CMT, Giedraitis V, Liewald D, Fischer K,
18 Mellstrom D, Larsson A, Wang Y, Scott WR, Lorentzon M, Beilby J, Ryan KA, Pennell CE, Vuckovic
19 D, Balkau B, Concas MP, Schmidt R, Mendes de Leon CF, Bottinger EP, Kloppenburg M,
20 Paternoster L, Boehnke M, Musk AW, Willemssen G, Evans DM, Madden PAF, Kahonen M, Kutalik Z,
21 Zoledziewska M, Karhunen V, Kritchevsky SB, Sattar N, Lachance G, Clarke R, Harris TB, Raitakari
22 OT, Attia JR, van Heemst D, Kajantie E, Sorice R, Gambaro G, Scott RA, Hicks AA, Ferrucci L,
23 Standl M, Lindgren CM, Starr JM, Karlsson M, Lind L, Li JZ, Chambers JC, Mori TA, de Geus E,
24 Heath AC, Martin NG, Auvinen J, Buckley BM, de Craen AJM, Waldenberger M, Strauch K,
25 Meitinger T, Scott RJ, McEvoy M, Beekman M, Bombieri C, Ridker PM, Mohlke KL, Pedersen NL,
26 Morrison AC, Boomsma DI, Whitfield JB, Strachan DP, Hofman A, Vollenweider P, Cucca F, Jarvelin
27 MR, Jukema JW, Spector TD, Hamsten A, Zeller T, Uitterlinden AG, Nauck M, Gudnason V, Qi L,
28 Grallert H, Borecki IB, Rotter JI, Marz W, Wild PS, Lokki ML, Boyle M, Salomaa V, Melbye M,
29 Eriksson JG, Wilson JF, Penninx B, Becker DM, Worrall BB, Gibson G, Krauss RM, Ciullo M, Zaza
30 G, Wareham NJ, Oldehinkel AJ, Palmer LJ, Murray SS, Pramstaller PP, Bandinelli S, Heinrich J,
31 Ingelsson E, Deary IJ, Magi R, Vandenput L, van der Harst P, Desch KC, Kooner JS, Ohlsson C,
32 Hayward C, Lehtimaki T, Shuldiner AR, Arnett DK, Beilin LJ, Robino A, Froguel P, Pirastu M, Jess T,
33 Koenig W, Loos RJF, Evans DA, Schmidt H, Smith GD, Slagboom PE, Eiriksdottir G, Morris AP,
34 Psaty BM, Tracy RP, Nolte IM, Boerwinkle E, Visvikis-Siest S, Reiner AP, Gross M, Bis JC, Franke
35 L, Franco OH, Benjamin EJ, Chasman DI, Dupuis J, Snieder H, Dehghan A and Alizadeh BZ.
36 Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight
37 Pathways that Link Inflammation and Complex Disorders. *Am J Hum Genet.* 2018;103:691-706.
- 38 22. Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, Krauss RM and
39 Stephens M. A multivariate genome-wide association analysis of 10 LDL subfractions, and their
40 response to statin treatment, in 1868 Caucasians. *PLoS One.* 2015;10:e0120758.
- 41 23. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
42 Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N,

- 1 Donnelly P and Marchini J. The UK Biobank resource with deep phenotyping and genomic data.
2 *Nature*. 2018;562:203-209.
- 3 24. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley JM,
4 Ramirez AH, Bowton E, Basford MA, Carrell DS, Peissig PL, Kho AN, Pacheco JA, Rasmussen LV,
5 Crosslin DR, Crane PK, Pathak J, Bielinski SJ, Pendergrass SA, Xu H, Hindorf LA, Li R, Manolio
6 TA, Chute CG, Chisholm RL, Larson EB, Jarvik GP, Brilliant MH, McCarty CA, Kullo IJ, Haines JL,
7 Crawford DC, Masys DR and Roden DM. Systematic comparison of phenome-wide association
8 study of electronic medical record data and genome-wide association study data. *Nat Biotechnol*.
9 2013;31:1102-10.
- 10 25. Li X, Meng X, Spiliopoulou A, Timofeeva M, Wei WQ, Gifford A, Shen X, He Y, Varley T,
11 McKeigue P, Tzoulaki I, Wright AF, Joshi P, Denny JC, Campbell H and Theodoratou E. MR-
12 PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic
13 instruments in UK Biobank. *Ann Rheum Dis*. 2018;77:1039-1047.
- 14 26. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-
15 McKay F, Kostadima MA, Lambourne JJ, Sivapalaratnam S, Downes K, Kundu K, Bomba L,
16 Berentsen K, Bradley JR, Daugherty LC, Delaneau O, Freson K, Garner SF, Grassi L, Guerrero J,
17 Haimel M, Janssen-Megens EM, Kaan A, Kamat M, Kim B, Mandoli A, Marchini J, Martens JHA,
18 Meacham S, Megy K, O'Connell J, Petersen R, Sharifi N, Sheard SM, Staley JR, Tuna S, van der
19 Ent M, Walter K, Wang SY, Wheeler E, Wilder SP, Lotchkova V, Moore C, Sambrook J, Stunnenberg
20 HG, Di Angelantonio E, Kaptoge S, Kuijpers TW, Carrillo-de-Santa-Pau E, Juan D, Rico D, Valencia
21 A, Chen L, Ge B, Vasquez L, Kwan T, Garrido-Martin D, Watt S, Yang Y, Guigo R, Beck S, Paul DS,
22 Pastinen T, Bujold D, Bourque G, Frontini M, Danesh J, Roberts DJ, Ouwehand WH, Butterworth AS
23 and Soranzo N. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common
24 Complex Disease. *Cell*. 2016;167:1415-1429 e19.
- 25 27. Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, Vaarhorst A, Kangas AJ,
26 Lyytikainen LP, Pirinen M, Pool R, Sarin AP, Soininen P, Tukiainen T, Wang Q, Tiainen M,
27 Tynkkynen T, Amin N, Zeller T, Beekman M, Deelen J, van Dijk KW, Esko T, Hottenga JJ, van
28 Leeuwen EM, Lehtimäki T, Mihailov E, Rose RJ, de Craen AJ, Gieger C, Kahonen M, Perola M,
29 Blankenberg S, Savolainen MJ, Verhoeven A, Viikari J, Willemsen G, Boomsma DI, van Duijn CM,
30 Eriksson J, Jula A, Jarvelin MR, Kaprio J, Metspalu A, Raitakari O, Salomaa V, Slagboom PE,
31 Waldenberger M, Ripatti S and Ala-Korpela M. Genome-wide study for circulating metabolites
32 identifies 62 loci and reveals novel systemic effects of LPA. *Nat Commun*. 2016;7:11122.
- 33 28. Ahola-Olli AV, Wurtz P, Havulinna AS, Aalto K, Pitkanen N, Lehtimäki T, Kahonen M,
34 Lyytikainen LP, Raitoharju E, Seppala I, Sarin AP, Ripatti S, Palotie A, Perola M, Viikari JS, Jalkanen
35 S, Maksimow M, Salomaa V, Salmi M, Kettunen J and Raitakari OT. Genome-wide Association
36 Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. *Am*
37 *J Hum Genet*. 2017;100:40-50.
- 38 29. MAGIC Consortium. MAGIC (the Meta-Analyses of Glucose and Insulin-related traits
39 Consortium). 2020;2020.
- 40 30. GIANT Consortium. GIANT: Genetic Investigation of ANthropometric Traits. 2020;2020.
- 41 31. Burgess S, Butterworth A and Thompson SG. Mendelian randomization analysis with
42 multiple genetic variants using summarized data. *Genet Epidemiol*. 2013;37:658-65.

- 1 32. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, Mindell JS,
2 Kivimaki M, Brunner EJ, Whittaker JC, Casas JP and Hingorani AD. Selecting instruments for
3 Mendelian randomization in the wake of genome-wide association studies. *Int J Epidemiol.*
4 2016;45:1600-1616.
- 5 33. Bowden J, Hemani G and Davey Smith G. Invited Commentary: Detecting Individual and
6 Global Horizontal Pleiotropy in Mendelian Randomization-A Job for the Humble Heterogeneity
7 Statistic? *Am J Epidemiol.* 2018;187:2681-2685.
- 8 34. Hartwig FP, Davey Smith G and Bowden J. Robust inference in summary data Mendelian
9 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.* 2017;46:1985-1998.
- 10 35. Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, Ayano M, Mitoma H,
11 Akahoshi M, Arinobu Y, Niuro H, Akashi K and Horiuchi T. Effects of tumor necrosis factor inhibitors
12 and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an
13 observational study. *PLoS One.* 2018;13:e0196368.
- 14 36. Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, Narazaki M and Tanaka
15 T. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody,
16 tocilizumab. *Ann Rheum Dis.* 2011;70:1164-5.
- 17 37. Liu C, Feng X, Li Q, Wang Y, Li Q and Hua M. Adiponectin, TNF-alpha and inflammatory
18 cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. *Cytokine.*
19 2016;86:100-109.
- 20 38. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J and Shoelson SE. Local and
21 systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med.*
22 2005;11:183-90.
- 23 39. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A and
24 Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. *JAMA*
25 *Cardiol.* 2019.
- 26 40. Georgakakis MK, Malik R, Anderson CD, Parhofer KG, Hopewell JC and Dichgans M. Genetic
27 determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein
28 cholesterol. *Brain.* 2020;143:597-610.
- 29 41. Allara E, Morani G, Carter P, Gkatzionis A, Zuber V, Foley CN, Rees JMB, Mason AM, Bell
30 S, Gill D, Lindstrom S, Butterworth AS, Di Angelantonio E, Peters J, Burgess S and consortium I.
31 Genetic Determinants of Lipids and Cardiovascular Disease Outcomes: A Wide-Angled Mendelian
32 Randomization Investigation. *Circ Genom Precis Med.* 2019;12:e002711.
- 33 42. HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F,
34 Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E and
35 Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. *N Engl J Med.*
36 2017;377:1217-1227.
- 37 43. Lanktree MB, Theriault S, Walsh M and Pare G. HDL Cholesterol, LDL Cholesterol, and
38 Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study. *Am J Kidney Dis.*
39 2018;71:166-172.
- 40 44. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W,
41 Shimokawa H, Everett BM and Glynn RJ. Modulation of the interleukin-6 signalling pathway and

- 1 incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab
2 Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J*. 2018;39:3499-3507.
- 3 45. Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, Cai TA, Damrauer S, Ahuja Y, Honerlaw J,
4 Huang J, Costa L, Schubert P, Hong C, Gagnon D, Sun YV, Gaziano JM, Wilson P, Cho K, Tsao P,
5 O'Donnell CJ, Liao KP and Program VAMV. Association of Interleukin 6 Receptor Variant With
6 Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide
7 Association Study. *JAMA Cardiol*. 2018;3:849-857.
- 8 46. Huber SA, Sakkinen P, Conze D, Hardin N and Tracy R. Interleukin-6 exacerbates early
9 atherosclerosis in mice. *Arterioscler Thromb Vasc Biol*. 1999;19:2364-7.
- 10 47. Akita K, Isoda K, Sato-Okabayashi Y, Kadoguchi T, Kitamura K, Ohtomo F, Shimada K and
11 Daida H. An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice. *Front*
12 *Cardiovasc Med*. 2017;4:84.
- 13 48. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F,
14 Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R,
15 Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M,
16 Rossi PRF, Troquay RPT, Libby P, Glynn RJ and Cantos Trial Group. Antiinflammatory Therapy with
17 Canakinumab for Atherosclerotic Disease. *N Engl J Med*. 2017;377:1119-1131.
- 18 49. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R,
19 Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC,
20 Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC
21 and Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J*
22 *Med*. 2019;381:2497-2505.
- 23 50. Rutherford AI, Subesinghe S, Hyrich KL and Galloway JB. Serious infection across biologic-
24 treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics
25 Register for Rheumatoid Arthritis. *Ann Rheum Dis*. 2018;77:905-910.
- 26 51. Thomsen SF. Epidemiology and natural history of atopic diseases. *Eur Clin Respir J*. 2015;2.
- 27 52. Isaacs JD, Harari O, Kobold U, Lee JS and Bernasconi C. Effect of tocilizumab on
28 haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
29 *Arthritis Res Ther*. 2013;15:R204.
- 30 53. Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S, Shang L, Malinge P,
31 Guilhot F, Chatel L, Hatterer E, Jones SA, Kosco-Vilbois MH and Ferlin WG. Although IL-6 trans-
32 signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the
33 induction of T cell-mediated autoimmunity. *J Immunol*. 2010;185:5512-21.

1 **Table 1. Mendelian Randomization results for clinical outcomes that were significantly**
 2 **associated with genetically downregulated IL6 signaling in UK Biobank.** The Odds
 3 Ratios (OR) and 95% confidence intervals (95%CI) are derived from inverse-variance
 4 weighted Mendelian randomization and are scaled to the CRP-decreasing effect of
 5 tocilizumab.

phecode	Description	N cases	N controls	OR (95%CI)	p-value
195	Cancer, suspected or other	879	248107	0.48 (0.33-0.70)	0.0002
223	Benign neoplasm of kidney and other urinary organs*	153	297014	4.24 (1.72-10.4)	0.002
250	Diabetes mellitus	16010	321754	0.81 (0.74-0.90)	2.1E-05
250.2	Type 2 diabetes	15097	321754	0.80 (0.73-0.89)	9.5E-06
334.2	Anterior horn cell disease*	165	304918	0.20 (0.08-0.50)	0.0005
396	Abnormal heart sounds	852	332812	0.48 (0.32-0.70)	0.0002
411	Ischemic Heart Disease	24925	312241	0.83 (0.77-0.90)	3.5E-06
411.3	Angina pectoris	13136	312241	0.76 (0.68-0.84)	1.6E-07
411.4	Coronary atherosclerosis	25105	312241	0.84 (0.77-0.90)	6.8E-06
411.8	Chronic ischemic heart disease, unspecified	24872	312241	0.84 (0.77-0.90)	6.4E-06
420.21	Acute pericarditis*	188	335549	3.82 (1.70-8.57)	0.001
442.11	Abdominal aortic aneurysm	726	330999	0.44 (0.29-0.67)	0.0001
454.1	Varicose veins, lower extremity	9179	306018	0.80 (0.71-0.90)	0.0003
458.9	Hypotension NOS	2849	231296	1.51 (1.22-1.87)	0.0001
495.2	Asthma with exacerbation	201	311025	3.62 (1.65-7.94)	0.001
506	Empyema and pneumothorax	927	328855	0.47 (0.32-0.69)	9.3E-05
519.2	Respiratory complications*	242	288235	0.28 (0.13-0.59)	0.0007
574.11	Cholelithiasis with acute cholecystitis*	1227	323752	1.76 (1.28-2.43)	0.0006
574.12	Cholelithiasis with other cholecystitis*	4489	323752	1.37 (1.16-1.63)	0.0003
591	Urinary tract infection	10044	313404	1.25 (1.12-1.41)	0.0001
597	Other disorders of urethra and urinary tract	709	326499	2.03 (1.33-3.10)	0.001
626.8	Infertility, female	1146	312766	1.79 (1.27-2.51)	0.0008
627.3	Postmenopausal atrophic vaginitis	908	312766	2.12 (1.46-3.07)	7.6E-05
681.3	Cellulitis and abscess of arm/hand	4502	328919	1.35 (1.14-1.61)	0.0006
681.5	Cellulitis and abscess of leg, except foot	4504	328919	1.34 (1.13-1.59)	0.0009
681.6	Cellulitis and abscess of foot, toe	4469	328919	1.34 (1.13-1.59)	0.0009
689	Disorder of skin and subcutaneous tissue NOS	33216	304955	1.13 (1.06-1.21)	0.0001
695.9	Unspecified erythematous condition	380	333072	2.90 (1.63-5.17)	0.0003
707.1	Decubitus ulcer	211	337065	0.28 (0.13-0.61)	0.001
939	Atopic/contact dermatitis due to other or unspecified	1696	333163	2.14 (1.62-2.82)	9.0E-08
733.2	Cyst of bone*	250	323543	3.80 (1.86-7.80)	0.0003
740.2	Osteoarthritis, generalized	480	314842	2.33 (1.39-3.89)	0.001
742.1	Loose body in joint*	276	307651	0.33 (0.16-0.66)	0.002

6 **Bold** indicates outcomes validated in meta-analysis of UK Biobank with PMBB and BioMe biobanks.
 7 The results presented are derived only from the UK Biobank.

1 * Outcomes not explored in validation cohorts due to low number of cases.

2 **Table 2. Mendelian Randomization results for biomarkers that were significantly**
3 **associated with genetically downregulated IL6 signaling.** The betas and 95% confidence
4 intervals (95%CI) are derived from inverse-variance weighted Mendelian randomization and
5 are scaled to the CRP-decreasing effect of tocilizumab.

Description	beta (95%CI)	p-value
C-reactive protein	-0.51 (-0.54 to -0.47)	1.9E-156
Cystatin C	-0.03 (-0.05 to -0.02)	2.1E-05
Granulocyte percentage of myeloid white cells	-0.10 (-0.13 to -0.07)	2.2E-11
Hematocrit	0.08 (0.06 to 0.11)	7.2E-09
Hemoglobin concentration	0.10 (0.07 to 0.13)	4.2E-12
Mean corpuscular hemoglobin	0.12 (0.09 to 0.15)	1.6E-15
Mean corpuscular hemoglobin concentration	0.07 (0.04 to 0.09)	4.8E-06
Mean corpuscular volume	0.10 (0.08 to 0.13)	3.3E-12
Monocyte count	0.08 (0.06 to 0.11)	1.6E-08
Monocyte percentage of white cells	0.11 (0.08 to 0.14)	5.6E-14
Red cell distribution width	-0.11 (-0.14 to -0.08)	5.6E-14
Cutaneous T-cell-attracting chemokine	0.41 (0.21 to 0.60)	3.7E-05
Interleukin-4	0.26 (0.13 to 0.39)	0.0002
Interleukin-6	0.31 (0.18 to 0.44)	3.8E-06
Glycated haemoglobin (HbA1c)	-0.07 (-0.08 to -0.05)	1.3E-14
HDL Cholesterol	0.04 (0.02 to 0.06)	5.9E-06
Cholesterol	0.04 (0.02 to 0.06)	1.9E-05

6

7

1 **Figure 1.** Flowchart of the significant associations for clinical outcomes.

2 k refers to number of outcomes

3 *weighted median, IVW restricted to 3 SNPs within IL6R

4 **9 outcomes non-significant in meta-analysis & 8 outcomes not available for analysis in validation
5 cohorts

6


7 **Figure 2.** Results of the phenome-wide association study (PheWAS) for clinical outcomes
8 in the UK Biobank and validation in PMBB and BioMe Biobanks.

9 Shown are the results from the inverse-variance weighted Mendelian randomization analyses in the
10 UK Biobank. The x-axes correspond to the logarithms of the p-values derived from these analyses.
11 The red lines correspond to the statistical significance level (FDR<0.05). Outcomes surviving all
12 significance criteria (Figure 1) in the UK Biobank analyses are labeled by name. Outcomes that were
13 further validated in the meta-analysis of UK Biobank with PMBB and BioMe biobanks are labeled in
14 black. Outcomes for which validation was unfeasible due to a low number of cases in both validation
15 cohorts are labeled in grey.

16


17 **Figure 3.** Results of the phenome-wide association study (PheWAS) for biomarkers.

18 Shown are the results from inverse-variance weighted Mendelian randomization analyses. The x-
19 axes correspond to the logarithms of the p-values derived from these analyses. The red lines
20 correspond to the statistical significance level (FDR<0.05). Solid circles correspond to outcomes that
21 survived all our significance criteria (**Supplementary Figure 2**). Open circles correspond to
22 outcomes that showed significant associations while there was significant heterogeneity between the
23 effects of the individual variants.




**Lower risk with IL6 signaling
downregulation**

←



**Higher risk with IL6 signaling
downregulation**

→



- Injuries/poisonings
- Symptoms
- Congenital anomalies
- Musculoskeletal
- Dermatologic
- Pregnancy complications
- Genitourinary
- Digestive
- Respiratory
- Circulatory system
- Sense organs
- Neurological
- Mental disorders
- Hematopoietic
- Endocrine/metabolic
- Neoplasms
- Infectious diseases

Lower with IL6 signaling
downregulation



Higher with IL6 signaling
downregulation

